After receiving my medical degree in 2012, I specialized in pulmonary medicine and practiced as a respiratory physician. Over nine years of practice, I was the attending physician for patients with acute and chronic respiratory diseases ranging from COVID-19 to lung cancer. I garnered a keen interest in the management of lung cancer because of the poor outcomes of my patients with current therapies; the summation of my clinical experiences inspired me to pursue basic research to develop new cancer treatments for my future patients.
In 2017, I entered the Keio University Graduate school of Medicine. During my graduate training, I elucidated a novel resistance mechanism of a third-generation EGFR-tyrosine kinase inhibitor osimertinib, the first-line treatment for EGFR mutation-positive non-small-cell lung cancer (Mol Cancer Res, 2020). Upon completing my Ph.D., I aspired to study in the U.S., believing it would provide me with in-depth knowledge of cancer biology, broad perspectives, various experiences, and many personal connections. Having considered the above, I was fortunate to begin my postdoctoral fellowship at UCSF in April 2021.